These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

895 related items for PubMed ID: 24313450

  • 1. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG, Toronto Bacterial Diseases Network, Canadian Public Health Laboratory Network.
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [Abstract] [Full Text] [Related]

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 3. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016.
    Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, McGeer A, Tyrrell GJ, Zhanel GG, Gubbay J, Hoang L, Levett PN, Van Caeseele P, Raafat Gad R, Haldane D, Zahariadis G, German G, Daley Bernier J, Strudwick L, Mulvey MR.
    Vaccine; 2018 Jul 25; 36(31):4701-4707. PubMed ID: 29937245
    [Abstract] [Full Text] [Related]

  • 4. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL.
    PLoS One; 2019 Jul 25; 14(12):e0226353. PubMed ID: 31834926
    [Abstract] [Full Text] [Related]

  • 5. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.
    Pediatr Infect Dis J; 2013 Jun 25; 32(6):604-9. PubMed ID: 23348816
    [Abstract] [Full Text] [Related]

  • 6. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E, Albert MJ.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [Abstract] [Full Text] [Related]

  • 7. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R, D'Ambrosio F, Del Grosso M, Pimentel de Araujo F, Caporali MG, Del Manso M, Gherardi G, D'Ancona F, Pantosti A, Pneumococcal Surveillance Group.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [Abstract] [Full Text] [Related]

  • 8. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M.
    PLoS One; 2015 Aug 16; 10(7):e0131494. PubMed ID: 26132078
    [Abstract] [Full Text] [Related]

  • 9. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P, Izquierdo C, Broner S, Muñoz-Almagro C, Hernández S, Ardanuy C, Pallarés R, Domínguez A, Jané M, Catalan Working Group on Invasive Pneumococcal Disease.
    Vaccine; 2018 Nov 29; 36(50):7744-7752. PubMed ID: 30473132
    [Abstract] [Full Text] [Related]

  • 10. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S, Fujisawa T, Ito Y, Chang B, Suga S, Noguchi T, Yamamoto M, Matsumura Y, Nagao M, Takakura S, Ohnishi M, Ihara T, Ichiyama S.
    Vaccine; 2016 Jan 02; 34(1):67-76. PubMed ID: 26602268
    [Abstract] [Full Text] [Related]

  • 11. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, Saitoh A, Oishi T, Hosoya M, Togashi T, Oishi K, Ihara T.
    Vaccine; 2015 Nov 09; 33(45):6054-60. PubMed ID: 26235372
    [Abstract] [Full Text] [Related]

  • 12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 13. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP.
    Pediatr Infect Dis J; 2013 Feb 15; 32(2):e45-53. PubMed ID: 23080290
    [Abstract] [Full Text] [Related]

  • 14. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 15. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM, Memish ZA, Al-Kattan KM.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [Abstract] [Full Text] [Related]

  • 16. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E.
    Vaccine; 2014 Jul 23; 32(34):4349-55. PubMed ID: 24657717
    [Abstract] [Full Text] [Related]

  • 17. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ, McIntosh ED, Reinert RR.
    Int J Infect Dis; 2010 Mar 23; 14(3):e197-209. PubMed ID: 19700359
    [Abstract] [Full Text] [Related]

  • 18. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P.
    Clin Infect Dis; 2014 Oct 15; 59(8):1066-73. PubMed ID: 25034421
    [Abstract] [Full Text] [Related]

  • 19. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA, Dascomb KK, Mehta RR, Stockmann C, Mason EO, Ampofo K, Pavia AT, Byington CL.
    Vaccine; 2016 Jan 20; 34(4):474-478. PubMed ID: 26706276
    [Abstract] [Full Text] [Related]

  • 20. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A, Toronto Invasive Bacterial Diseases Network.
    Clin Infect Dis; 2016 Jan 15; 62(2):139-47. PubMed ID: 26354970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.